Merck & Co Inc

More Details of Merck & Co Inc Company

Merck & Co., Inc. is a research-intensive biopharmaceutical company engaged in research to deliver health solutions that advance the prevention and treatment of diseases in people and animals. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It is also engaged in developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase.

Company Info

Company codeMRK

Company nameMerck & Co Inc

IPO dateJan 01, 1941

Founded at1970

CEOMr. Robert M. (Rob) Davis

Number of employees75000

Security typeOrdinary Share

Fiscal year-endJan 01

Address2000 Galloping Hill Road

CityKENILWORTH

Stock exchangeNYSE Consolidated

CountryUnited States of America

Postal code07033

Phone19087404000

Websitehttps://www.merck.com/

Company codeMRK

IPO dateJan 01, 1941

Founded at1970

Company Executives

Name

Name/Position

Position

Shareholding

Change

Mr. Robert M. (Rob) Davis

Chairman of the Board, President, Chief Executive Officer

443.60K

+27.35%

Mr. Sanat Chattopadhyay

Executive Vice President and President - Merck Manufacturing Division

185.33K

+17.90%

Dr. Dean Y. Li, M.D., Ph.D.

Executive Vice President, President - Merck Research Laboratories

78.86K

+70.54%

Ms. Caroline Litchfield

Chief Financial Officer, Executive Vice President

74.34K

+46.03%

Mr. Chirfi Guindo

Senior Vice President, Chief Marketing Officer - Human Health

66.61K

+73.22%

Ms. Jennifer L. Zachary

Executive Vice President, General Counsel, Corporate Secretary

53.42K

+90.81%

Mr. Michael A. Klobuchar

Executive Vice President, Chief Strategy Officer

23.22K

+1.98%

Mr. Joseph Edward Romanelli

Senior Vice President, President - MSD International Human Health

20.72K

+5.86%

Ms. Patricia F. Russo

Independent Director

13.15K

--

Mr. Thomas Henry (Tom) Glocer, J.D.

Lead Independent Director

5.10K

--

Name

Name/Position

Position

Shareholding

Change

Mr. Robert M. (Rob) Davis

Chairman of the Board, President, Chief Executive Officer

443.60K

+27.35%

Mr. Sanat Chattopadhyay

Executive Vice President and President - Merck Manufacturing Division

185.33K

+17.90%

Dr. Dean Y. Li, M.D., Ph.D.

Executive Vice President, President - Merck Research Laboratories

78.86K

+70.54%

Ms. Caroline Litchfield

Chief Financial Officer, Executive Vice President

74.34K

+46.03%

Mr. Chirfi Guindo

Senior Vice President, Chief Marketing Officer - Human Health

66.61K

+73.22%

Ms. Jennifer L. Zachary

Executive Vice President, General Counsel, Corporate Secretary

53.42K

+90.81%

Revenue Breakdown

Currency: USDUpdate time: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Oncology-Keytruda

29.48B

45.95%

Vaccines -Gardasil/Gardasil

8.58B

13.38%

Animal Health-Livestock

3.46B

5.39%

Other pharmaceutical

2.51B

3.91%

Vaccines -ProQuad/M-M-R II/Varivax

2.48B

3.87%

Other

17.65B

27.50%

By RegionUSD

Name

Revenue

Proportion

United States

32.28B

50.30%

Europe, Middle East and Africa

14.04B

21.88%

China

5.49B

8.56%

Latin America

3.46B

5.39%

Japan

3.28B

5.11%

Other

5.62B

8.75%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Oncology-Keytruda

29.48B

45.95%

Vaccines -Gardasil/Gardasil

8.58B

13.38%

Animal Health-Livestock

3.46B

5.39%

Other pharmaceutical

2.51B

3.91%

Vaccines -ProQuad/M-M-R II/Varivax

2.48B

3.87%

Other

17.65B

27.50%

Shareholder

Update time: Tue, Mar 11

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

10.03%

BlackRock Institutional Trust Company, N.A.

5.68%

State Street Global Advisors (US)

4.79%

Wellington Management Company, LLP

3.20%

Geode Capital Management, L.L.C.

2.42%

Other

73.89%

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

10.03%

BlackRock Institutional Trust Company, N.A.

5.68%

State Street Global Advisors (US)

4.79%

Wellington Management Company, LLP

3.20%

Geode Capital Management, L.L.C.

2.42%

Other

73.89%

Type

Shareholder

Proportion

Investment Advisor/Hedge Fund

35.88%

Investment Advisor

31.44%

Research Firm

3.76%

Pension Fund

2.96%

Bank and Trust

2.38%

Hedge Fund

1.52%

Sovereign Wealth Fund

1.49%

Insurance Company

0.69%

Family Office

0.11%

Other

19.77%

Institutional Shareholding

Update time: Thu, Feb 20

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

5313

2.05B

81.05%

+16.08M

2024Q4

5410

2.04B

80.88%

+11.87M

2024Q3

5200

2.01B

79.47%

-7.96M

2024Q2

5181

2.01B

79.28%

-4.86M

2024Q1

5154

2.00B

78.88%

-6.10M

2023Q4

5065

1.99B

78.60%

+584.81K

2023Q3

4871

1.98B

78.17%

-32.03M

2023Q2

4864

2.00B

78.94%

-18.54M

2023Q1

4818

1.99B

78.43%

-16.95M

2022Q4

4785

1.98B

77.94%

-5.23M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

253.26M

10.03%

+3.27M

+1.31%

Feb 28, 2025

BlackRock Institutional Trust Company, N.A.

143.39M

5.68%

+10.26M

+7.71%

Dec 31, 2024

State Street Global Advisors (US)

120.91M

4.79%

+1.88M

+1.58%

Dec 31, 2024

Wellington Management Company, LLP

80.74M

3.2%

+4.93M

+6.51%

Dec 31, 2024

Geode Capital Management, L.L.C.

61.18M

2.42%

+2.03M

+3.43%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

34.98M

1.38%

+1.17M

+3.47%

Dec 31, 2024

Fidelity Management & Research Company LLC

33.58M

1.33%

-11.95M

-26.24%

Dec 31, 2024

BofA Global Research (US)

23.08M

0.91%

-1.38M

-5.65%

Dec 31, 2024

BlackRock Asset Management Ireland Limited

21.22M

0.84%

+1.34M

+6.77%

Dec 31, 2024

Morgan Stanley Smith Barney LLC

20.63M

0.82%

-290.99K

-1.39%

Dec 31, 2024

Related ETFs

Update time: Sun, Apr 6

Name

Proportion

FT Vest DJIA Dogs 10 Target Income ETF

11.99%

First Trust NASDAQ Pharmaceuticals ETF

6.57%

VanEck Pharmaceutical ETF

5.04%

TBG Dividend Focus ETF

4.77%

Amplify Weight Loss Drug & Treatment ETF

4.76%

Invesco Pharmaceuticals ETF

4.51%

VictoryShares Free Cash Flow ETF

4.51%

Tema Oncology ETF

4.49%

Vaneck Durable High Dividend ETF

4.48%

Proshares Ultra Health Care

4.26%

FT Vest DJIA Dogs 10 Target Income ETF

Proportion11.99%

First Trust NASDAQ Pharmaceuticals ETF

Proportion6.57%

VanEck Pharmaceutical ETF

Proportion5.04%

TBG Dividend Focus ETF

Proportion4.77%

Amplify Weight Loss Drug & Treatment ETF

Proportion4.76%

Invesco Pharmaceuticals ETF

Proportion4.51%

VictoryShares Free Cash Flow ETF

Proportion4.51%

Tema Oncology ETF

Proportion4.49%

Vaneck Durable High Dividend ETF

Proportion4.48%

Proshares Ultra Health Care

Proportion4.26%

Dividend

A total of 35.12B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Jan 28, 2025

MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025

Mar 17, 2025

Apr 07, 2025

Mar 17, 2025

Nov 19, 2024

MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024

Dec 16, 2024

Jan 08, 2025

Dec 16, 2024

Jul 23, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024

Sep 16, 2024

Oct 07, 2024

Sep 16, 2024

May 29, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024

Jun 17, 2024

Jul 08, 2024

Jun 17, 2024

Jan 23, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024

Mar 15, 2024

Apr 05, 2024

Mar 14, 2024

Nov 28, 2023

MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023

Dec 15, 2023

Jan 08, 2024

Dec 14, 2023

Jul 25, 2023

MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Oct 06, 2023 going ex on Sep 14, 2023

Sep 15, 2023

Oct 06, 2023

Sep 14, 2023

May 23, 2023

MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Jul 10, 2023 going ex on Jun 14, 2023

Jun 15, 2023

Jul 10, 2023

Jun 14, 2023

Jan 24, 2023

MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Apr 10, 2023 going ex on Mar 14, 2023

Mar 15, 2023

Apr 10, 2023

Mar 14, 2023

Nov 30, 2022

MRK.NB Final Cash Dividend of gross USD 0.73 paid on Jan 09, 2023 going ex on Dec 14, 2022

Dec 15, 2022

Jan 09, 2023

Dec 14, 2022

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

78.930USD

Merck & Co Inc

78.930

Overview

Company